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ABSTRACT
PAX8 is a member of the Paired box (PAX) multigene family of 
transcription factors, which are involved in the tissue-specific control of the 
expression of several genes during development of both vertebrates and 
invertebrates. Previously, PAX8 has been studied as key molecular marker and 
regulator of follicular thyrocyte differentiation, but recent evidence show that 
PAX8 is also expressed in specific types of tumors. In particular, PAX8 results 
to be expressed in human ovarian cancer subtypes and Fallopian tubal 
secretory cells from which the ovarian cancer may originate. However, the 
functional role of PAX8 in the carcinogenesis of ovarian cancer has not been 
addressed yet.
In this study, we investigated the potential role of PAX8 in ovarian 
cancer progression, using in vitro ovarian cancer cells and in vivo mouse 
xenograft models. To this purpose, stable PAX8 depleted ovarian cancer cells 
(SKOV-3) were generated using short hairpin RNA (shRNA) constructs. Cell 
proliferation, motility and invasion potential of PAX8 silenced cells were 
analyzed by means of growth curves, wound healing and matrigel assays. 
Furthermore, PAX8 knockdown and control cells were injected into nude mice 
for xenograft tumorigenicity assay. The results obtained in vitro showed that 
PAX8 is involved in the regulation of proliferation, migration and invasion of 
ovarian cancer cells. In addition, PAX8 silencing strongly suppresses cellular 
anchorage-independent growth in vitro and, notably, tumorigenesis in vivo in 
the nude xenograft mouse model. Overall, these results indicate that PAX8 
plays an important role in the tumorigenic phenotype of ovarian cancer cells.
Finally, to identify new genes and pathways modulated by PAX8 in 
ovarian cancer, an expression profile analysis was performed by RNA 
sequencing (RNA-seq) of PAX8 knockdown ovarian cancer cell (SKOV-3) 
and Fallopian tube cells (FT-194). Twenty-four hours after PAX8 knockdown 
in SKOV-3 and FT-194, 182 and 164 genes were found to be modulated, 
respectively. These genes resulted to be correlated to different biological 
pathways involved in cancer progression. This is the first RNA-seq study that 
compares genes regulated by PAX8 in ovarian cancer cells and Fallopian tube 
cells. The identification of the biological pathways and target genes controlled 
by PAX8 will have considerable importance to understand ovarian cancer 
progression as well as to set up novel therapeutic strategies.
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1. BACKGROUND
1.1 Ovarian cancer: incidence, pathogenesis and classification
Worldwide, approximately 200.000 women are diagnosed with ovarian 
cancer annually, with an estimated 100.000 associated deaths (Jemal et al. 
2011). Although ovarian cancer accounts for only 3% of all cancers in women, 
it has one of the highest death-to-incidence ratios, which has been primarily 
attributed to the unavailability of effective screening tools, to the absence of 
early phase symptomatology in many patients, and to its typical presentation at 
advanced stages when the prognosis is poor (Jemal et al. 2008). One of the 
greatest obstacles to the detection of early-stage ovarian cancer is our poor 
understanding of its histogenesis and pathogenesis.
The origins of ovarian cancer are complex and still under debate. 
Several models have been posited to explain how epidemiological factors such 
as menstruation and ovulation may lead to ovarian cancer (Figure 1).
Figure 1. Incessant Ovulation hypothesis and Gonadotropin hypothesis for ovarian  
cancer pathogenesis (from Emori et al., 2014)
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A long standing hypothesis, called the Incessant Ovulation hypothesis, 
suggests that the repetitive wounding and healing of the ovarian surface 
epithelium and adjacent tubal epithelium, that is induced by monthly ovulation, 
increases cell proliferation and thus the likelihood of genomic instability which 
could lead to oncogenesis (Emori and Drapkin 2014). Another hypothesis, 
known as the Gonadotropin hypothesis, implicates excessive direct and indirect 
stimulation of the ovarian surface epithelium by gonadotropins, leading to 
differentiation, proliferation, and ultimately malignant transformation (Cramer 
and Welch 1983). More recently, the Incessant Menstruation hypothesis 
suggests that repeated retrograde menstruation exposes the ovary and Fallopian 
tubes to the genotoxic effects of reactive oxygen species and iron-associated 
oxidative stress (Vercellini et al. 2011). Lastly, several recent papers have 
focused on damage induced by inflammation-mediated factors found in the 
follicular fluid (Backman et al. 2014, Lau et al. 2014). The recurring theme in 
all these hypotheses is the incessant ovulatory damage that reinforces the 
importance of ovulation in ovarian cancer progression, but also makes it 
difficult to separate the impact of each hypothesis as they are physiologically 
interconnected. Women with altered steroid hormone levels, such as those with 
Polycystic Ovarian Syndrome, tend to ovulate sporadically and to rarely 
develop ovarian cancer as well as women who take oral contraceptives and 
receive the protective benefits of both lowered gonadotropin levels and 
inhibited ovulation (McCartney et al. 2002). However, the average age of 
ovarian cancer onset is postmenopausal, at age 63, when hormonal levels have 
shifted and ovulation has stopped (Emori and Drapkin 2014). Thus, an 
unanswered question that also remains is why menopause is so temporally 
important to the onset of the disease.
Based on morphologic, immunohistochemical and molecular data, a 
dualistic model of ovarian carcinogenesis has been proposed that classifies 
ovarian carcinomas into 2 groups: type I and type II. (Figure 2)
Figure 2. Classification of ovarian carcinomas into type I and type II.
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Type I tumors include low-grade serous carcinomas (LG-SC), low-
grade endometrioid carcinomas, clear cell and mucinous carcinomas that are 
not clinically aggressive and generally present at early stage. They rarely 
harbor TP53 mutations, but instead display mutations involving specific cell 
signalling pathways, including KRAS, BRAF, ERBB2, PTEN, CTNNB1, 
PIK3CA, ARID1A, and PPP2R1A. Women with LG-SC had prolonged 
median survival of 81 months compared to 57–65 months in those with high-
grade epithelial ovarian cancer (Ozlos et al. 2003, Gershenson et al. 2006, 
Armstrong et al. 2006). Pathologic findings show that 60% of LG-SC are 
associated with a low malignant potential (LMP) neoplasm, whereas it was 
found in only 2% of high-grade ovarian carcinomas. Moreover, recurrent 
serous ovarian tumors with LMP are mostly low-grade lesions and have slow 
progression (Crispens et al. 2002, Malpica et al. 2004).
Type II tumors, which include high-grade serous carcinomas (HGSC), 
high-grade endometrioid carcinomas, malignant mixed mesodermal tumors 
(carcinosarcomas), and undifferentiated carcinomas, frequently display TP53 
mutations and are genetically unstable (Kurman and Shih 2011). High-grade 
malignancies tend to be fast growing and chemosensitive, and the low-grade 
neoplasms typically grow slowly, but are less sensitive to chemotherapy (Shih 
and Kurman 2004). Lifetime ovulation is positively correlated with HGSC, the 
most common type II tumor, and factors, such as birth control which decreases 
lifetime ovulation, have a protective effect against HGSC (Cramer and Welch 
1983). Thus, establishing the molecular mechanisms linking ovulation to 
HGSC pathogenesis could be critical to develop new screening techniques and 
treatments for the disease.
1.2 Genetic and protein alteration in ovarian cancer
Genetic and protein alterations in tumor cells also support the idea that 
the different types of ovarian cancers have unique pathogenesis (Table 1).
Characteristic Low-grade High-grade
TP53 inactivity Rare 50-80%
HLA-G Rare 61%
HER2/neu amplification Rare 20-66%
AKT amplification Rare 12-30%
Apoliprotein E expression 12% 66%
BRAF mutation 30-50% Rare
KRAS mutation 30-50% Rare
PTEN mutation 20% (endometrioid) Rare
MSI 50% (endometrioid) 8-28%
ARID1A mutation 30% (endometrioid) Rare
Table 1. Variability in biology of low- and high-grade tumors (modified from 
Saad et al., 2010)
Gene analyses have shown that BRAF, KRAS, and PTEN mutations 
occur more often in low-grade tumors compared to high-grade tumors (30–
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50% versus 20%, respectively) (Singer et al. 2003a, Shih and Kurman 2004). 
Conversely, HLA-G, HER2, and AKT levels are increased in high-grade 
tumors (61%, 20–66%, and 12–30%, respectively) as compared to low-grade 
tumors (Singer et al. 2003b). While TP53 is found to be mutated in >80% of 
high-grade tumors, it is rarely mutated in low-grade tumors (Brachova et al. 
2013). 
As described in Table 2, several other oncogenes have been found 
deregulated in epithelial ovarian cancer (EOC).
Protein Function Rate in EOC
 EGFR (HER-1) Membrane TK receptor, promotes growth 35–70%
 HER-2 Membrane TK receptor, promotes growth 20–66% (HGS)
 Src TK, promotes growth, angiogenesis, survival 80–90%
 CSF-1/fms Ligand/receptor, inhibits anoikis 50–70%
 ILGF/ILGFR Peptide hormone/receptor, promotes growth 21–25%
 KRAS G-protein, promotes growth through MAP kinase 
pathway
30–50% (LGS)
 BRAF Promotes growth through MAP kinase pathway 30–50% (LGS)
 TGF-β Ligand, inhibits growth through Rb activation Lost in 40%
 Myc Transcription factor, cell cycle mediator 30%
 Cyclin D/Cdk4/6 Advance from G1 to S phase 30–90%
 Cyclin E/Cdk2 Advance from G1 to S phase 30–70%
 Cyclin B/Cdk1 Advance cell cycle into M phase 80%
 p16 Inhibits cyclin D/Cdk4/6 Lost in 30%
 p27 (kip-1) Inhibits cyclin E/Cdk2 Lost in 55%
 p21 (WAF-1) Inhibits cyclin B/Cdk1 Lost in 25–40%
 PIP3/Akt Akt (activated by PIP3) inhibits apoptosis 12–18% (HGS)
 PTEN Decrease Akt 20% (Endo)
 p53 Promotes cell cycle arrest/apoptosis with DNA damage 50–90% (HGS)
 BRCA1 Co-factor for transcription factors, “caretaker” of genome 6–82%a
 BRCA2 Co-factor for transcription factors, “caretaker” of genome 1–3%
 MLH1/MSH2 Mediates mismatch repair, promotes genetic stability 30% (Endo)
 Fas ligand Produced by tumor cells to induce apoptosis of T-cells 50–80%
 HLA-G Secreted by tumor cells to inhibit cytotoxic immune cells 61% (HGS)
 hTERT Subunit of telomerase, maintains telomere length 80–85%
 VEGF/VEGFR Ligand/receptor complex induces angiogenesis 40–100%
 EphA2 TK promotes angiogenesis and vasculogenic mimicry 76%
 MMPs Matrix metalloproteinases degrade extracellular matrix 40–100%
 αvβ3 Integrin, promotes survival and angiogenesis 95%
 FAK Co-factor TK promotes adhesion, proliferation, survival 70%
 E-cadherin Promotes adhesion 90–100%
Table 2. Main contributors to ovarian carcinogenesis (modified from Saad et al.,  
2010)
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The tyrosine kinase Src plays a functional role in cell proliferation, 
adhesion, angiogenesis, and cell survival (Ishizawar and Parsons 2004, Silva 
2004, Han et al. 2006), and in chemotherapeutic drug resistance (Pengetnze et 
al. 2003). Src over-expression is found in 93% of late-stage ovarian cancers 
and in more than 80% of ovarian cancer cell lines (Wiener et al. 2003). 
Inhibiting Src proto-oncogene results in the diminished growth of ovarian 
cancer in mouse models through inhibition of angiogenesis (Han et al. 2006).
Another group of proteins that result to be altered in ovarian 
tumorigenesis includes the type I tyrosine kinase receptor family HER (Erb) 
that comprises four monomers: EGFR (epidermal growth factor receptor, HER-
1), HER-2 (proto-oncogene neu), HER-3, and HER-4. EGFR is over-expressed 
in 35– 70% of epithelial ovarian cancers (Bartlett et al. 1996), while HER-2 is 
over-expressed in 20–30% of ovarian cancer cases (Leary et al. 1992).
The oncoprotein RAS is a G-protein involved in cell proliferation. 
KRAS mutations have been detected in 61% of borderline tumors, 68% of low-
grade tumors, 50% of mucinous adenocarcinomas, and only in 5% of high-
grade serous carcinomas (Suzuki et al 2000, Singer et al. 2003a). However, 
only 19% of the LG-SC shows KRAS mutations (Wong et al. 2010). 
Activating mutations in BRAF have also been identified in ovarian tumors. An 
extensive study on BRAF and KRAS mutations performed in 264 epithelial 
and non-epithelial ovarian neoplasms showed that BRAF mutations occur 
exclusively in LG-SC (33 of 91, 36%) whereas KRAS mutations were 
identified in 26 of 91 (29.5%) LG-SC, 7 of 49 (12%) high-grade serous 
carcinomas, 2 of 6 mucinous adenomas, 22 of 28 mucinous borderline tumors, 
and 10 of 18 mucinous carcinomas. Of note, two serous borderline tumors were 
found to harbor both BRAF and KRAS mutations (Sieben et al. 2004).
At least 10% of all epithelial ovarian cancers are hereditary, with 
mutations in the BRCA genes accounting for approximately 90% of cases 
(Swisher 2003, Coupier et al. 2004, Prat et al. 2005). Hereditary ovarian 
cancers exhibit distinct clinicopathologic features compared with sporadic 
cancers. The cumulative lifetime risk of ovarian cancer is 40% to 50% for 
BRCA1 mutation carriers and 20% to 30% for BRCA2 mutation carriers. Both 
BRCA proteins participate in the transcriptional regulation of gene expression 
as well as the recognition or repair of certain forms of DNA damage, 
particularly double-strand breaks. Frame-shift or non-sense mutations of 
BRCA1 and BRCA2 are the most common. Most ovarian cancers associated 
with germline BRCA mutations are diagnosed at a younger age and are high-
grade and advanced-stage serous carcinomas. BRCA mutations do not seem to 
play a significant role in the development of mucinous or borderline ovarian 
tumors. Hereditary ovarian cancers have a distinctly better clinical outcome 
with longer overall survival and recurrence-free interval after chemotherapy 
than sporadic cancers (Prat et al. 2005).
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1.2 The Fallopian tubes as origin site for high-grade serious ovarian 
carcinoma
Ovarian carcinoma was traditionally thought to originate from the 
ovarian surface epithelium (OSE) or ovarian epithelial inclusions (OEI), and 
investigative efforts at early detection have accordingly been centered on the 
ovary for decades. However, these efforts have not been successful, as 
evidenced by the fact that the overall survival for women with ovarian cancer 
has not changed in any fundamental manner over the last 50 years. Several 
emerging lines of evidence indicate that some traditional knowledge of ovarian 
epithelial carcinogenesis and cellular origination are fundamentally incorrect.
Recently, studies on both asymptomatic women with germline BRCA1 
or BRCA2 mutations as well as those from the general population with pelvic 
serous carcinoma, have detected precancerous or early cancerous lesions, 
serous tubal intraepithelial carcinoma (STIC), in the Fallopian tubal fimbria 
(Colgan et al. 2001, Powell et al. 2005, Medeiros et al. 2006). Furthermore, a 
spectrum of potential precursor lesions to serous carcinomas, including the 
‘p53 signatures’ and the ‘secretory cell outgrowth’, have similarly been 
described in the Fallopian tube fimbria (Karst et al. 2014) (Figure 3).
Figure 3. Illustration of the proposed carcinogenic sequence for serious  
tumorigenesis from the Fallopian tube epithelium (from Karst et al.,  
2014)
In addition, STIC lesions, which are defined as in situ cancers with 
TP53 mutations and increased proliferative capacity, are observed in at least 
60% of women with HGSC of the ovary and/or peritoneum (Kindelberger et al. 
2007; Przybycin et al. 2010) while similar in situ lesions are not observed in 
the OSE (Folkins et al. 2008). Such early lesions exhibit shortened telomeres, a 
notable hallmark of early molecular carcinogenesis (Kuhn et al. 2011, Chene et 
al. 2013). Clinical observations support the hypothesis that STICs can originate 
from secretory epithelial cells of the Fallopian tubes and progress to HGSC by 
rapidly disseminating to involve ovarian and peritoneal surfaces.
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This hypothesis is further supported by the shared morphologic and 
immunophenotypic features of STICs and HGSCs. In addition, injection of 
transformed primary human Fallopian tube secretory epithelial cells (FTSECs) 
into the peritoneum of nude mice induces tumors that from histological, 
immunophenotypical and genomic point of view resemble human HGSCs 
(Karst et al. 2011, Jazaeri et al. 2011). However, these associations are largely 
circumstantial and necessitate experimental proof in order to confirm the role 
of FTSECs and STICs in serous carcinogenesis. From those and other studies, 
the Fallopian tube has emerged as an important potential source for female 
pelvic serous carcinomas, resulting in a paradigm shift that will likely have 
important implications for future detection, therapy and prevention in ovarian 
cancer. Thus, these new theories furthermore suggest that different ovarian 
tumor subtypes have different origins, with the ovarian surface epithelium 
implicated in type 1 tumors and Fallopian tube secretory epithelial cells 
implicated in HGSC (Levanon et al. 2008, Kurman and Shih 2010, Karst and 
Drapkin 2010).
Recently, it has been demonstrated that HGSC originates from the 
Fallopian tubal secretory epithelial cells that are positive for PAX8 expression 
(Perets et al. 2013). The identification of specific markers of the precursor 
Müllerian duct cells from the coelomic epithelium within normal endometrial 
and tubal mucosa provides strong evidence that supports the new carcinogenic 
hypothesis. These markers maintain their expression not only in endometrial or 
tubal tumors, but also in certain types of ovarian and peritoneal tumors. Within 
this context falls PAX8 protein that serves as an important marker for 
discriminating ovarian carcinomas from breast carcinomas, with greater 
sensitivity and specificity than Wilms tumor protein and it is particularly useful 
for the diagnosis of clear cell and endometrioid types of ovarian cancer. 
Although gene expression profiling studies have indicated that the transcription 
factor PAX8 is a potential diagnostic marker for ovarian carcinoma (Hibbs et 
al. 2004), the molecular mechanism by which PAX8 is involved in the 
carcinogenesis of these tumors remains unclear and requires further studies. 
1.4 The transcription factor PAX8
PAX8 is a member of the PAX gene family that encodes for DNA 
binding proteins involved in the regulation of the development of various 
tissues in different species. The PAX gene family consists of nine well-
described transcription factors (PAX1-9) highly conserved in vertebrates, and 
all these proteins are characterized by the presence of a Paired box. This 
specific sequence encodes for the Paired domain, a very important domain for 
recognizing the target sequences on the DNA. The Paired domain is composed 
of 128 amino acids and it is subdivided in two fundamental sub-domains, one 
at N-terminus, the other at the C-terminus, called PAI and RED, respectively. 
Each of these domains contains a helix-turn-helix motif and both domains are 
connected through a linker region (Mansouri et al. 1998) (Figure 4).
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Figure 4. Schematic structure of a PAX protein
The subdivision of the Paired domain into 2 independent domains 
reflects the ability of PAX proteins to bind DNA in different ways and, overall, 
to recognize different consensus sequences. Considering the homology of the 
Paired domains the nine PAX proteins can be subdivided in different groups 
(Figure 5).
Figure 5. PAX family members subgroups
The nine PAX proteins are divided into four subgroups based on the 
presence or absence of structural regions such as the DNA-binding 
homeodomain, the partial homeodomain and the octapeptide motif. All PAX 
genes contain the Paired domain and all contain an octapeptide region with the 
exception of PAX4 and PAX6. PAX2, 5 and 8 are characterized by the 
presence of an octapeptide and a partial homeodomain.
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The temporal and spatial expression patterns of PAX genes are tightly 
regulated, and their expression is observed primarily during fetal development 
(Dahl et al. 1997). In most cases, PAX gene expression attenuates when 
development is complete, but in a few tissues it persists into adult life. 
Although abnormal cell growth and proliferation is often associated with high 
expression levels of PAX genes in adults (Muratovska et al. 2003), 
nevertheless, the precise role that PAX genes play in cancer is still unclear. 
During embryonic development, the protein PAX8 is expressed in thyroid, 
kidney, Muller system and nervous system (Pasca Di Magliano et al. 2000). It 
has been demonstrated to be required for both the morphogenesis of the thyroid 
gland and the maintenance of the thyroid differentiated phenotype. In addition 
to a key role in thyrocyte differentiation (Pasca Di Magliano et al. 2000), 
PAX8 is also required for the development of the Mullerian duct (Plachov et al. 
1990). Indeed, PAX8 knockout mice have defects in the development of the 
Mulleran duct (Mittag et al. 2007), have a small thyroid, and show a severe 
hypothyroidism phenotype (Mansouri et al. 1998). Mutations of the PAX8 
gene are among the genetic defects responsible for congenital hypothyroidism 
(De Felice and Di Lauro 2004).
In addition to its role in the pathogenesis of hypothyroidism, PAX8 also 
plays a role in the progression of follicular thyroid carcinomas and adenomas 
(Nonaka et al. 2008). It results to be overexpressed in the majority of gliomas, 
Wilms tumors and well-differentiated pancreatic neuroendocrine tumors 
(Poleev et al. 1992, Sangoi et al. 2011). Moreover, PAX8 is one of the top 40 
genes specifically expressed in different types of ovarian carcinomas (Schaner 
et al. 2003). PAX8 is not expressed in the surface epithelial cells of the ovary, 
but its expression was found in 96% of serous ovarian carcinomas, in 89% of 
endometrioid and 100% of clear cell carcinomas (Nonaka et al. 2008). This 
observation could be justified by the fact that these tumors originate from 
Fallopian tubes cells where PAX8 is expressed.
1.5 PAX8 in Fallopian tubes and ovarian cancer
The transcription factor PAX8 is essential for the development of the 
female genital tract, including the Fallopian tubes but not the ovaries (Mittag et 
al. 2007). In fact, the female PAX8- / - mice are infertile because they lack a 
functional uterus revealing only remnants of myometrial tissue. In addition, the 
vaginal opening is absent. The infertility in PAX8-/- mice seems to be due to a 
defect in the development of the Mullerian duct rather than to hormonal 
imbalance, pointing to a direct morphogenic role for PAX8 in uterine 
development. 
In the Fallopian tube epithelium (FTE), PAX8 is a marker of the 
secretory cell lineage, not of the ciliated cell population (Figure 6).
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Figure 6. PAX8 is positive in secretory cells of Fallopian tube fimbria but not in  
ciliated cells (modified from Laury et al. 2011)
(left) Haematoxilin and eosin staining of the Fallopian tube fimbria;  
(right) Immunohistochemistry (IHC) for PAX8 in the Fallopian tube  
fimbria.
Consistent with its role as a lineage marker (Bowen et al. 2007, Cheung 
et al. 2011), PAX8 expression is retained in the Fallopian tube cells during the 
process of secretory cell malignant transformation, both in STIC lesions and in 
the vast majority of HGSCs (Laury et al. 2010, Laury et al. 2011, Tacha et al. 
2011) (Figure 7).
Figure 7. Expression of PAX8, a specific Müllerian lineage marker, during  
Fallopian tube malignant transformation (modified from Perets et al.,  
2013)
(A, B) Immunohistochemistry (IHC) for PAX8 in the human FTE is shown  
for the benign epithelium (top) and STIC (bottom). The square area in (A)  
is shown at a higher magnification in (B). PAX8 positive FTSEC and  
PAX8-negative ciliated cells (CIL) are demarcated by red arrows. (C)  
IHC for PAX8 in human HGSC.
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PAX8, initially identified in normal cells originating in Müllerian ducts, 
is also present in ovarian neoplasia (Tong et al. 2011, Tacha et al.2011), and it 
is characteristic for the epithelial phenotypes (serous, clear cell, and 
endometrioid) but mesothelial cells stain negative for PAX8 (Figure 8).
Figure 8. Immunohistochemistry staining of PAX8 in EOC (modified from Liliac  
et al., 2013)
Consequently, the positive expression of PAX8 strongly supports the 
origin of ovarian carcinoma in the fimbrial area of Fallopian tubes or in 
endometriosis foci (Mhawech-Fauceglia et al 2012). Moreover, PAX8 
expression allows the differentiation between Müllerian and non-Müllerian 
origin in the case of ovarian metastatic carcinomas that could derive from a 
primary tumor in pancreas, colon or mammary gland. The ovary is a common 
site for the formation of metastases and the breast is one of the most common 
sources. Ovarian and breast cancers develop from hormonally responsive 
tissues, comprise various histopathological subtypes, and exhibit considerable 
variability in clinical manifestations and prognosis. Metastatic breast  
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carcinoma is known to morphologically mimic primary ovarian carcinoma, 
resulting in difficulty in distinguishing between these forms of cancer. PAX8 is 
stained in none of the breast and almost all ovarian cancer samples, indicating 
that PAX8 is a valuable marker for the differential diagnosis of ovarian and 
breast cancer (Nikiforov 2011). Ovarian cancers are frequently associated with 
metastases, which are commonly found in peritoneal fluids (Edge et al 2010). 
Thus, PAX8 positive staining appears to be highly specific and sensitive for 
detecting metastatic ovarian serous carcinoma in cytological preparations, and 
may prove useful for distinguishing these cells from mesothelial cells in fluid 
cytology (McKnigh et al 2010). In addition, PAX8 detection is useful for 
recognition of metastatic carcinomas in pelvic washings, particularly in cases 
with suspicious cytology (Xiang et al 2012).
There are gaps in the literature with respect to direct links between PAX 
gene expression and mechanisms of tumor generation. The available data 
indicate that PAX genes in adult tissues may not be themself oncogenes but 
they may contribute to the malignant phenotype by sustaining abnormal cell 
proliferation. In agreement with previous data that indicated the role of PAX 
genes in cell survival (Bouchard et al. 2000, Ostrom et al 2000, Porteous et al 
2000), the analysis of kidneys obtained from PAX2-PAX8 double knochout 
mice shows an increase in apoptotic cell death (Narlis et al 2007). Similarly, 
the silencing of PAX8 in differentiated thyroid cells highlighted its new role in 
the regulation of cell survival and proliferation (Di Palma et al. 2013).
In conclusion, numerous evidences demonstrate the importance of 
specific PAX proteins such as PAX8 as prognostic markers for cancers and/or 
potentially targets for novel anti-cancer therapies.
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2. AIMS OF THE STUDY
Recent studies have shown that Fallopian tube secretory cells 
expressing PAX8 are the origin of the high-grade serious carcinoma(HGSC),a 
subtype of ovarian cancer, that account for 90% of the cases among these 
tumors.
A genome-wide screening of pooled shRNAs in 25 ovarian cancer cell 
lines identified the transcription factor PAX8 as amplified in primary high-
grade ovarian tumors and essential for survival and proliferation of this type of 
tumor (Cheung et al., 2011). Furthermore, recent studies from our research 
group have demonstrated that PAX8 is involved in cell survival and 
proliferation of thyroid differentiated epithelial cells (FRTL-5) (Di Palma et al., 
2013). Thus the main objective of this study was to investigate the role of 
PAX8 in the tumorigenic phenotype of ovarian cancer cells.
To this aim we investigate whether interfering with PAX8 expression in 
cellular models of ovarian cancer would translate into a reduction of cell 
survival, migration and in vivo tumorigenicity. In particular, the specific aims 
of this research included: in vitro evaluation of PAX8 involvement in cellular 
proliferation, migration and invasion of SKOV-3 ovarian cancer cell line stably 
silenced for PAX8; in vivo assessment of the tumorigenic properties of PAX8 
through injection of PAX8 silenced clones into nude mice and evaluation of the 
tumor growth. Finally, the last aim was the identification of potential PAX8 
target genes in the ovarian cancer and Fallopian tubes cells by trascriptome 
analysis of transiently PAX8 silenced SKOV-3 and FT-194 cells.
Overall, the findings of this study may contribute to a better 
understanding of the role of PAX8 in the progression of ovarian epithelial 
carcinomas and to the identification of new direct or indirect targets of PAX8, 
thus opening the way to novel diagnostic and therapeutic approaches for such 
aggressive cancers.
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3. MATERIALS AND METHODS
3.1 Cell culture and transfection assay
SKOV-3, TOV-21G, OVCAR-3 and TOV-112D ovarian cancer cells 
were grown in RPMI medium (Euroclone) supplemented with 10% foetal 
bovine serum (FBS). Fallopian tube cell line FT-194 was grown in F12/DMEM 
medium containing 2% Ultroser G Serum Substitute for Animal Cell Culture 
(USG).
For stable transfection experiments, FUGENE 6 reagent (Promega) was 
used for SKOV-3, according to the manufacturer's instructions. The 
DNA/FUGENE ratio was 1:3 in all the experiments. Forty-eight hours later, 
transfected SKOV-3 cells were selected in the presence of 0.4 μg/ml of 
puromycin (Sigma-Aldrich). For stable transfection experiments, cells were 
plated at 5 × 105 cells/100-mm tissue culture dish 24 h prior to transfection 
with 2 µg of proper DNA.
For transient transfections, Lipofectamine (Invitrogen) was used for FT-
194 and SKOV-3 cell line according to the manufacturer's instructions. Briefly, 
cells were plated at a density of 2x104 per well and were transfected in 
triplicate with 5 nM of PAX8 siRNA or siRNA non targeting.
3.2 shRNA and siRNA
Five shRNA targeting PAX8, Mission shRNA lentiviral plasmids 
(SHCLNG-NM_003466, Sigma-Aldrich) and MISSION non-targeting shRNA 
control vector (SHC002, Sigma-Aldrich) were used for the stable transfection 
of SKOV-3 cells.
PAX8 siRNA (silencer select Pre-designed siRNA ID:s15403, and 
silencer select negative control #1 siRNA, AMBION) were used for transient 
transfection of FT-194 cells and SKOV-3 cells. 
3.3 RNA extraction, RT-PCR analysis and quantitative real time PCR
Total RNA was prepared using TRIzol reagent (Invitrogen) according 
to the manufacturer’s directions. Total RNA (1µg) was retrotranscribed using 
iScript cDNA Synthesis kit (Bio-Rad Laboratories). The cDNAs were used for 
both classic PCR reaction and real-time PCR. The real time PCR analysis was 
performed using iCycler-iQ real-time detection system and SYBER green 
chemistry (Bio-Rad Laboratories). To design the primers for qRT-PCR assays, 








Reactions were carried out in duplicate in three independent 
experiments. For each gene, the data reported are the mean value ±SD of three 
independent experiments, normalized by the expression of the housekeeping 
gene, and expressed as a percentage of the value measured in parental FT-194. 
To calculate the relative expression levels, we used the 2-DDCT method (Livak 
and Schmittgen 2001).
3.4 Protein extract and immunoblotting
Cells were washed twice with ice-cold PBS and lysed in a buffer 
containing 10 mM HEPES (pH 7.9), 400 mM NaCl, 0,1 mM EGTA (pH 7.8),  
5% glycerol, 1 mM dithiothreitol, and 1mM phenylmetilsulfonil fluoride. The 
protein concentration was determined using the Bio-Rad protein assay (BioRad 
Laboratories).
For Western blotting analysis, proteins were separated on SDS-PAGE, 
and blotted onto PVDF membranes (Immobilon-P, Millipore). The primary 
antibodies used were: rabbit polyclonal anti-PAX8, actin (Santa Cruz 
Biotechnology) mouse monoclonal anti-GAPDH (Santa Cruz Biotechnology). 
Secondary antibodies anti-rabbit or anti-mouse IgG-HRP whole antibody (GE-
Healthcare) were used as suggested by manufacturers. The filters were 
developed using an enhanced chemiluminescence (ECL) detection method 
(Pierce) according to the manufacturer’s instructions.
3.5 Immunofluorescence and confocal laser scanning microscopy
Cells were grown directly on glass coverslips for 48-72 h, fixed in 4% 
paraformaldehyde solution in PBS for 20 min at room temperature, treated for 
20 min with 50 mM solution of NH4Cl in PBS, permeabilized for 10 min in 
0.2% Triton X-100 in PBS, and incubated for 60 min in 0.5% BSA (bovine 
serum albumin) in PBS. The coverslips were subsequently incubated at 4°C for 
1 h with rabbit polyclonal anti-PAX8 diluted 1:1000 in 0.5% BSA in PBS and, 
after PBS washing, incubated for 30 min with Alexa Fluor-594 goat anti-rabbit 
IgG-TRITC (Vinci Biochem) diluted 1:200 in 0.5% BSA in PBS. After final 
washings with PBS, the coverslips were mounted on a microscope slide using a 
50% solution of glycerol in PBS. Images were collected with a Zeiss LSM 510 
confocal laser scanning microscope, equipped with a 543 nm HeNe laser, and a 
Plan-Apochromat 63/1.4 oil immersion objective. Emitted fluorescence was 
detected using LP 560 long pass filter for TRITC.
3.6 Cell proliferation assay
SKOV-3, SKOVCtrl-, siCl32, and siCl48 cells were plated at 8 × 104 
cells in 60-mm plate and every day cells were counted for 6 days using a Bio-
rad instrument for cell count (TC-10).
3.7 Wound-healing assay
Confluent SKOVCtrl-, siCl32, and siCl48 cells plated on tissue culture 
dishes were grown until confluent and wounded by manual scratching with 
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200-μl pipette tip, washed with PBS and incubated at 37°C in complete media. 
At the indicated time points, phase contrast images at specific wound sites 
were captured.
3.8 In vitro invasion assay
Cell invasion assay was examined using a reconstituted extracellular 
matrix (Matrigel; BD Biosciences). Filters (8 μm pore size) on the bottoms of 
the upper compartment of the transwells (6,5 mm; Corning) were coated with 2 
mg/ml of Matrigel. 2 × 105 cells were suspended in 100 μl of RPMI with 0.2% 
FBS. The cells were then plated onto the coated wells and incubated at 37°C 
for 16 h. Medium in the lower compartment was supplemented with 5% FBS 
as a chemoattractant. Non-invading cells were removed from the top of the 
wells with a moistened cotton swab. Cells that penetrated the membrane were 
fixed with 11% glutaraldehyde and stained with 0.1% crystal violet. The 
concentration of solubilized crystal violet in 10% acetic acid was evaluated as 
absorbance at 590 nm.
3.9 Anchorage-independent growth in soft agar
Cells were mixed in RPMI 2X (Sigma-Aldrich Aldrich), tryptose 
phosphate buffer, and 1.25% of Noble Agar (Difco Laboratories Inc.), and 
plated in 60-mm dishes on the top of 1% agar base. The colonies were allowed 
to grow in incubator at 37°C, 5% CO2 for 2 to 3 weeks. The images of cell 
colonies were captured with an inverted microscope.
3.10 Animal experiments
All animal studies were conducted at Biogem Scarl Ariano Irpino, AV 
(Italy), Preclinical Research and Development Service. Nude female NOD-
SCID mice (NOD-CB17/PRKDC/J) were purchased from Charles River 
Laboratories International, Wilmington, MA. To generate xenografts, human 
ovarian cancer cells were cultured in RPMI with 10% heat-inactivated FBS. 24 
six-week-old nude female NOD-SCID mice were randomly assigned to four 
groups: the SKOV-3 group (n = 6), SKOV-3Ctrl- group (n = 6), siCl32 group 
(n = 6) and siCl48 group (n = 6). They were injected subcutaneously in the both 
flanks with 7×106 cells suspended in 0.2 ml PBS/Matrigel Matrix GF (1:1) (BD 
Biosciences). Mice were daily monitored for clinical signs and mortality. Body 
weight recordings were carried out weekly. Tumor growth was measured twice 
a week with a Mitutoyo caliper. The formula TV (mm3) =  [length (mm) × 
width (mm)2]/2 was used. At the end of the study mice were sacrificed by 
cervical dislocation and tumors were collected.
3.11 RNA sequencing
Three independent silencing experiments were performed for each 
condition (si-PAX8 or si-CTR) and were used for RNA sequencing analysis 
(RNA-seq). Three µg of total RNA extracted from the three biological 
replicates using the RNeasy Mini kit (Qiagen), from FT-194 and SKOV-3 
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cells, 24 h after transfection, were sent to the Service Analysis Genomix4Life 
of Salerno University. RNA samples were sequenced using the Illumina 
TruSeqTM system (Illumina) according to manufacturer’s protocols.
3.12 Data analysis
To perform differential expression analysis, FASTQ files were 
processed for sequence quality check using FASTQC. The TopHat2 software 
was used to align the raw RNA-seq FASTQ short reads to the human reference 
genome (GRCh37/hg19). Counting of the reads for each gene was performed 
using HTSeq (version 0.6.0). The Bioconductor package edgeR was used for 
differential gene expression analysis and genes exhibiting a log2 fold change ≥ 
0,6 and p-value (FDR) ≤ 0.05 were considered differentially expressed in FT-
194 and SKOV-3 cells. Gene ontology (GO) and pathway functional class 
scoring were performed using the Gene Set Analysis Toolkit V2 (Zhang et al, 
2004).
The promoter regions of genes co-regulated after PAX8 silencing were 
analyzed in order to recognize DNA binding motifs for both PAX8_01 and 
PAX8_B matrices. Genes mostly expressed in FT-194 and SKOV-3 cells were 
selected for the transcription factors binding site (TFBS) analysis using the 
web-based PASTAA (predicting associated transcription factors from 
annotated affinities) method (Roider et al 2009), which utilizes the prediction 
of binding affinities of a transcription factor to promoters. The list of 
downregulated and upregulated genes were ranked respectively according to 
the prediction of binding affinity of their promoter regions to the PAX8 
binding sites, with the following criteria: range for promoter region from -2000 
to 0 at either side of the transcription start site, conserved mouse/human 
sequence block, maximum affinity across promoter range.
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4. RESULTS
4.1 PAX8 expression in human ovarian cancer cell lines
The expression of PAX8 in human ovarian cancer cell lines was 
examined by RT-PCR and Western Blotting analysis. Total RNA was extracted 
from SKOV-3 (serous carcinoma), TOV-21G (clear cell carcinoma), TOV-
112D (endometrioid carcinoma) and OVCAR-3 (serous carcinoma) cells and 
1µg of RNA was used to synthesize the respectively cDNAs that were used for 
RT-PCR with specific primers for PAX8. As shown in Figure 9A, PAX8 is 
expressed in all cell lines with the exception of TOV-112D. In addition, we 
evaluated the expression of PAX8 in ovarian cancer cell line by Western blot 
analysis of protein extracts prepared from SKOV-3, TOV-21G, TOV-112D 
and OVCAR-3 ovarian cancer cells. As shown in Figure 9B, the polyclonal 
antibody that specifically recognizes PAX8 revealed the presence of a protein 
of the predicted relative molecular mass in SKOV-3, TOV-21G and OVCAR-3 
ovarian cancer cell lines, whereas it resulted to be undetectable in TOV-112D 
cells.
          A
           B
Figure 9. Expression of PAX8 in human ovarian cancer cell lines
A. RT-PCR was performed using total RNA from SKOV-3, TOV-21G, TOV-112D  
and OVCAR-3 ovarian cancer cells and β-actin mRNA was amplified as control
B. Protein extracts from SKOV-3, TOV21G, TOV112D and OVCAR-3 cells were  
subjected to SDS-PAGE and Western blot with a specific anti-PAX8 antibody.  









Furthermore, the subcellular localization of PAX8 protein in these cell 
lines was analyzed by immunofluorescence. To address this issue, SKOV-3, 
TOV-21G and TOV-112D cells were grown directly on glass coverslips and 
were processed for immunofluorescence analysis with a specific anti-PAX8 
polyclonal antibody. The signals from the PAX8 immunostaining were 
acquired at high resolution by line-wise scanning microscopy. PAX8 was 
observed exclusively in the nuclei of SKOV-3 and TOV-21G cells as expected 
being PAX8 a transcriptional factor, while TOV-112D resulted negative at the 
staining for PAX8 as expected on the basis of the results obtained from RT-
PCR and Western blot analysis (Figure 10).
Figure 10. PAX8 immunofluorescence staining in ovarian cancer cells lines
SKOV-3, TOV-21G and TOV-112D cells were grown directly on glass coverslips  
and stained for immunofluorescence with the anti-PAX8 antibody. The  
fluorescence signals were acquired at a confocal microscope by line-wise  
scanning. The staining for PAX8 was detected only in the nuclei of the cells.
4.2 Silencing of PAX8 expression in SKOV-3 cells
To investigate the role of PAX8 in the tumorigenic properties of 
ovarian cancer cells, we silenced its expression in the SKOV-3 cell line using 
shRNA plasmid vectors. In particular, SKOV-3 cells were transfected with 2 
µg of a pool of five plasmid vectors, each containing an shRNA against 
different region of PAX8 cDNA, and with the empty vector as control (see 
Materials and Methods). Forty-eight hours after transfection, the selection with 
the specific antibiotic, puromycin, was started, and about sixty independent 
clones were isolated. The silencing of PAX8 expression in the stable clones 
was examined by Western blotting analysis of protein extracts prepared from 
each clone. The screening analysis of all the clones allowed the identification 
of two clones, named siCl32 and siCl48, with different levels of PAX8 
expression silencing, as shown in Figure 11A. These results were confirmed by 
immunofluorescence followed by confocal fluorescence microscopy. As shown 
in Figure 11B, the signal from the PAX8 protein acquired at high resolution by 
line-wise scanning indicated that the siCl32 and siCl48 clones expressed 
different silencing levels of PAX8 with respect to the SKOV-3 control 
(SKOVCtrl-). These clones were selected for all further studies.
SKOV-3 TOV-21G TOV-112D
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Figure 11. Western blotting and immunofluorescence for PAX8 in two independent  
representative clones (siCl32 and siCl48)
A. Total protein extracts prepared from each stable clone were separated on  
SDS-PAGE and subjected to Western blotting analysis with a specific PAX8  
antibody. The hybridization with actin assessed the protein uniform loading and  
integrity. B. Stable SKOVCtrl-, siCl32 and siCl48 clones were processed for the  
immunofluorescence assay with a specific PAX8 polyclonal antibody.
4.3 Effects of PAX8 silencing on proliferation, migration and invasion of 
SKOV-3 cells
To examine whether PAX8 expression could directly contribute to the 
tumorigenicity of ovarian cancer cells, we analyzed whether PAX8 silencing 
was able to modify the oncogenic properties of SKOV-3 cells. First, we 
analyzed the proliferation rate of the above mentioned SKOV-3 stable clones 
by growth curves experiments. 80,000 cells of each stable clones were plated at 
time (t=0) and counted each day for six days. As shown in Figure 12, PAX8 
expression confers a proliferative advantage to SKOV-3 cells; in fact, the 
proliferation rate of each clone resulted PAX8 dose-dependent and was 







Figure 12. PAX8 silencing in SKOV-3 cells inhibits cell proliferation
Growth curves of SKOV-3, SKOVCtrl-, siCl32, and siCl48 cells are shown.  
Triplicate of 8 ×104 cells were seeded into 60-mm plate. Cell numbers were  
counted on days 1, 2, 3, 4, 5 and 6 after seeding.
Moreover, in order to investigate the role of PAX8 in cell migration and 
invasion, wound healing and transwell assays were performed. In the wound 
healing assays, we compared the cell motility of the siCl32 and siCl48, 
independent stable clones, with that of SKOVCtrl- cells transfected with the 
empty vector. After 8 h, the area of the wound was significantly recovered by 
migrating SKOVCtrl- cells and after 24 h the wound area was completely re-
covered, as shown in Figure 13. In contrast, the motility of the siCl32 and 
siCl48 clones stable silenced for PAX8 at 8 and 24 h was significantly 
decreased, as shown in Figure 13. These results well correlate with PAX8 
expression levels, suggesting that PAX8 silencing significantly reduces the 
migration of SKOV-3 cells.
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Figure 13. PAX8 silencing in SKOV-3 cells reduces cell migration
Wound-healing migration assay for SKOVCtrl-, siCl32, and siCl48 was  
performed. The healing of wounds by migrated cells at time 0, 8 and 24 h is  
shown. The siCl32 and siCl48 cells migrate slower than SKOVCtrl-.
Finally, to further study the effect of PAX8 silencing in SKOV-3 cells 
in in vitro invasion assay, we performed a transwell migration assay in which 
cells were seeded in serum-free medium on the top chamber of a 2-chamber 
transwell cell culture plate. Colorimetric evaluation of the cells migrated to the 
lower chamber revealed that the invasiveness of the siCl32 and siCl48 was 
decreased with respect to SKOVCtrl- clone, as represented in Figure 14. These 
results indicate that PAX8 is involved in cell migration and invasion 
capabilities of ovarian cancer cells.
Figure 14. PAX8 silencing in SKOV-3 cells reduces in vitro invasion







4.4 Effects of PAX8 silencing on tumorigenesis in vivo and in vitro of 
SKOV-3 cells
To investigate the role of PAX8 in the tumorigenicity of SKOV-3 cells 
in vitro and in vivo we performed soft agar and nude mice assays. We seeded 
the cells in plates containing 1.25% noble agar. After incubation at 37°C for 21 
days, we observed that the siCl32 and siCl48 clones were not able to grow 
efficiently in soft agar and to form colonies. They formed only small 
aggregations of cell debris, while SKOVCtrl- clone efficiently grew on soft 
agar (Figure 15).
Figure 15. PAX8 silencing in SKOV-3 cells reduces in vitro anchorage-
independent growth
Soft agar growth assay of SKOVCtrl-, siCl32 and siCl48 clones was performed  
and photographed after 21 days.
These results suggested that PAX8 is essential for anchorage-
independent growth of SKOV-3 cells.
Subsequently, to examine PAX8 role in in vivo tumorigenesis, 
SKOVCtrl-, siCl32, siCl48 clones and parental cells were separately injected 
subcutaneously into the flanks of nude mice, and the growth of the tumors was 
monitored. To this aim, we have grown 7x106 cells of each clone, suspended in 
0.2 ml PBS/Matrigel Matrix GF (1:1) and send them to the Biogem facility for 
injection into nude female NOD-SCID mice. Every week after implantation, 
the tumor size was measured with calliper and the tumor growth represented by 
volume was reported in Figure 16A. As shown in this figure, SKOV-3 parental 
cells formed tumors with the same efficiency as the SKOVCtrl- cells, while 
siCl32 and siCl48 cells were able to form smaller tumors with respect to 
SKOVCtrl- cells, as also indicated by the tumor sizes excised from the 
sacrificed mice (Figure 16B). 
All together these data emphasize the involvement of PAX8 in in vitro 
and in vivo tumorigenesis.
siCl48SKOVCtrl- siCl32
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A                B
Figure 16. PAX8 silencing reduces tumorigenesis in nude mice
A. Growth curves of tumor size measured for 7 weeks after injection by calliper.  
B representative images of the tumors from nude mice injected with SKOV-3,  
SKOVCtrl-, siCl32 and siCl48 cells.
4.5 PAX8 expression in human Fallopian tube cell line (FT-194)
Recent studies have demonstrated that many serous ovarian carcinomas 
can originate from Fallopian tubal secretory epithelial cells (Perets et al, 2013). 






first examined the expression of PAX8 in the FT-194 cells by Western blotting 
analysis. As shown in Figure 17A, the polyclonal antibody that specifically 
recognizes PAX8 revealed the presence of a protein of the predicted relative 
molecular mass in FRTL-5 cells, used as positive control, SKOV-3 and FT-194 
cell lines. In addition, we evaluated the expression of PAX8 by qRT-PCR. To 
this end, total RNA was extracted from SKOV-3 cells and FT-194 cells, from 
Fallopian tube tissue (OriGene Technologies), and from normal ovary tissue 
(OriGene Technologies) used as positive and negative control, respectively. 
Figure 17B shows that PAX8 is expressed in SKOV-3 cells, FT-194 cells and 
Fallopian tube tissue while it is absent in the normal ovary tissue.
Figure 17. Expression of PAX8 in FT-194 epithelial fallopian tube cells
A. Total protein extracts prepared from all cell lines were separated on SDS-
PAGE and subjected to Western blot analysis with a specific anti-PAX8 antibody.  
The hybridization with GAPDH assessed the protein uniform loading and  
integrity. B. qRT-PCR analysis was performed on total RNA prepared from all  







Furthermore, the subcellular localization of PAX8 protein in FT-194 
cell line was analyzed by immunofluorescence. To address this issue, SKOV-3 
cells used as a positive control, and FT-194 cells were grown directly on glass 
coverslips and all cells were processed for immunofluorescence assay with a 
polyclonal anti-PAX8 antibody. The signals from the PAX8 immunostaining 
were acquired at high resolution by line-wise scanning microscopy. The results 
indicated that PAX8 was present exclusively in the nuclei of SKOV-3 and FT-
194 cells as expected being PAX8 a transcriptional factor (Figure18).
Figure 18. PAX8 immunofluorescence staining in FT-194 cells
SKOV-3 and FT-194 cells were grown directly on glass coverslips and stained  
for immunofluorescence assay with the anti-PAX8 antibody. The fluorescence  
signals were acquired at a confocal microscope by line-wise scanning. The  
staining for PAX8 was detected only in the nuclei of the cells.
4.7 Genome-wide identification of PAX8 target genes in SKOV-3 and FT-
194 cells through RNA Sequencing Analysis
To investigate the role of the transcription factor PAX8 in Fallopian 
tube differentiation and in ovarian cancer disease, we transiently silenced 
PAX8 expression using the specific PAX8 siRNA.
In particular, FT-194 and SKOV-3 cells were transfected, with 5 nM of 
specific PAX8 siRNA or 5 nM of scramble siRNA used as control (see 
Materials and Methods). The decrease of PAX8 expression was detected 24 h 




Figure 19. Transient silencing of PAX8 expression in FT-194 and SKOV-3 cells
A. Total protein extracts prepared from FT-194 and SKOV-3 cells were  
separated on SDS-PAGE and subjected to Western blot analysis with a specific  
anti-PAX8 antibody. The hybridization with GAPDH assessed the protein  
uniform loading and integrity. B. qRT-PCR analysis was performed on total RNA  
prepared from all the samples and the expression of PAX8 was measured.
The RNAs obtained from SKOV-3 and FT-194 cells 24 h after 
transfection with siRNA against PAX8 or scrambled sequence siRNA were 
used to perform RNA sequencing analysis (RNA-Seq), in order to identify 
genes differentially expressed in PAX8 knockdown SKOV-3 and FT-194 
samples. This study is the first RNA-Seq-based gene expression analysis of 
PAX8 target genes undertaken in Fallopian tube cells and ovarian cancer cells. 
The RNA obtained 24 h after transfection from the two cell lines was sent to 
the Service Analysis Genomix4Life of Salerno University for sequencing 
libraries generation. Three independent biological samples of siPAX8 FT-194 
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and SKOV-3 were submitted to IlluminaTruSeq sequencing platform, and the 
raw data were analyzed by Prof. Michele Ceccarelli (BioGeM s.c.a.r.l, Institute 
of Genetic Research "Gaetano Salvatore" Ariano Irpino, Italy). A total of 182 
and 164 genes differentially expressed with a log2 Fold change ≥ 0,6 and 
corrected p-value (FDR) ≤ 0.05 were obtained for SKOV-3 and FT-194 cells, 
respectively. In SKOV-3 cells of 182 genes, 45 were up-regulated and 137 
were down-regulated as shown by the Smearplot (Figure 20A), while in FT-
194 cells of 164 genes, 46 were up-regulated and 118 down-regulated (Figure 
20B).
Figure 20 Smear plot, representing the mean of expression values among all  
samples (x axis) and fold change between the two conditions (y axis)
A, SKOV-3 cells; B, FT-194 cells.
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Gene Ontology (GO), used to categorize biological processes that are 
over-represented in PAX8 transiently knockdown SKOV-3 and FT-194 cells, 
demonstrated that the most affected categories were: cancer and reproductive 
system disease, cellular growth and proliferation, cell death and survival, and 
cellular movement. Accordingly, the most affected pathways included the 
regulation of epithelial-mesenchymal transition, p53 signalling and apoptosis, 
cyclins and cell cycle regulation, ovarian cancer signalling, as well as other 
cancer pathways. 
However, it was uncertain whether these transcripts level changes were 
caused by direct PAX8 regulation or cascade reactions. Since the goal of our 
study was the identification of novel PAX8 targets in Fallopian tube cells and 
ovarian cancer cells, a strategy was performed to reduce the number of false 
positive targets by merging the data obtained from two independent 
experiments, in order to obtain the common genes modulated by PAX8 
silencing. As shown in Figure 21, 35 up-regulated and 138 down-regulated 
genes were common in two cell lines.
Figure 21 Venn diagram showing the comparison between PAX8 knockdown  
SKOV-3 and FT-194 cells








To identify PAX8 direct targets, the common genes were analyzed for 
the presence in their 5’-flanking regions of PAX8 binding consensus sequences 
and were ranked according to their affinity score to PAX8_01 and PAX8_B 
matrices ≥ 1.4 using the PASTAA Method (Roider et al, 2009). A total of 125 
genes could be PAX8 putative direct targets considering a score between 0,75 
to 1, and of these 20 genes showed a higher PAX8 binding score (0,99).
Pathway analysis from the 125 common genes found as putative targets 
of PAX8 showed that many pathways were perturbed upon PAX8 silencing in 
SKOV-3 and FT-194 (Figure 22). These pathways include: cell death and 
survival, cell cycle, reproductive system development and function, cellular 
growth and proliferation, organ development, cancer, reproductive system 
disease, tumor morphology, cell to cell signalling and interaction and cellular 
movement.
Figure 22 Pathway analysis of 125 common genes differentially expressed in  
siPAX8 SKOV-3 and FT-194.
Pathway-Express software was used to identify the pathways most affected  
by the common genes.
Therefore, it is likely that in the list of the genes that resulted from the 
PASTAA analysis there are many interesting PAX8 targets to be further 




Epithelial ovarian cancer is a morphologically and biologically 
heterogeneous disease and remains a leading cause of morbidity and mortality 
in female affected by cancer of the reproductive system. It accounts for 
approximately 3% of all cancers in women and despite considerable efforts to 
improve early detection and advances in chemotherapy, the highest mortality 
rate of ovarian cancers has markedly increased worldwide. In literature there is 
ample evidence that dysregulated expression or activation of specific members 
of the PAX family play a major role in the progression of specific cancers 
arising in those organ systems in which PAX proteins exert developmental 
functions during embryogenesis (Robson et al. 2006). However, the precise 
role of PAX proteins in cancer is still unclear. 
Recently, a genome-scale analysis of 102 cancer cell lines identified 
PAX8 as a lineage-specific survival gene, highly expressed in ovarian cancer 
lines and amplified in a substantial fraction of primary ovarian tumors (Cheung 
et al. 2011). Thus, in order to elucidate the role of PAX8 in ovarian cancer, in  
vitro and in vivo studies were performed using different ovarian cancer cell 
lines and nude mice models. In particular, we first analyzed the expression of 
PAX8 at both mRNA and protein level in SKOV-3, TOV-21G, TOV-112D and 
OVCAR-3 ovarian cancer cell lines. PAX8 resulted to be expressed in all the 
cell lines with the exception of TOV-112D cells. We chose the SKOV-3 cell 
line to assess PAX8 involvement in ovarian tumorigenesis and we silenced the 
expression of PAX8 gene in these cells to evaluate the effect of PAX8 
knockdown on the cellular proliferation, migration and invasion, that represent 
the main biological processes involved in cancer progression. In particular, two 
stable cell clones constitutively silenced by PAX8 shRNA, namely siCl32 and 
siCl48, were selected to study the function of the transcription factor in 
epithelial ovarian cancer cells. Our results demonstrated that PAX8 knockdown 
elicits a dramatic effect on SKOV-3 cell growth, inhibits the invasion rate of 
these cells through the Matrigel, and reduces the migration rate of the cells in a 
wound-healing assay. Interestingly, the effect of PAX8 silencing on cellular 
responses was more pronounced using the siCl48 clone rather than the siCl32 
clone reflecting different levels of PAX8 knockdown. Similar results showing 
the effects of PAX8 silencing on epithelial cell survival and proliferation in the 
rat thyrocyte cell line FRTL-5 have been reported (Di Palma et al., 2013).
Furthermore, to study the tumorigenic effects of PAX8 silencing in  
vitro we seed both siCl32 and siCl48 clones into soft agar plates and after an 
incubation at 37°C for 21 days they were not able to grow efficiently in soft 
agar and to form colonies, thus suggesting that PAX8 is essential for 
anchorage-independent growth of SKOV-3 cells. To assess the ability of PAX8 
to inhibit tumor growth in vivo, we injected siCl32, siCl48 clones and parental 
SKOV-3 cells into nude female NOD-SCID mice. The results obtained 
demonstrated a reduction of tumor growth in the mice injected with siCl32 and 
siCl48 clones with respect to mice injected with parental cells, thus suggesting 
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that PAX8 silencing is capable of reduce in vivo the tumor growth. The size of 
palpable lesions well correlated with PAX8 expression levels of the single 
clones, confirming the role of PAX8 as oncogene in vivo. Our data provide the 
first evidence of a clear involvement of PAX8 in the in vivo tumorigenesis of 
ovarian cancer cells. 
Recent evidences showed that high-grade serous carcinoma (HGSC) 
originates in the Fallopian tubal secretory epithelial cells, which are positive 
for PAX8 expression (Perets et al. 2013), thus prompting us to see if a subset 
of PAX8 target genes is relevant for cancer initiation or maintenance by 
identifying novel PAX8 targets both in ovarian cancer and Fallopian tube cells. 
In order to define the transcriptional networks functionally regulated by PAX8 
as well as to identify its direct and indirect targets, we performed transient 
RNA interference to knockdown PAX8 gene expression in FT-194 and SKOV-
3 cells and we analyzed the gene expression profile by RNA sequencing 
(RNA-seq). The results obtained suggest that PAX8 regulates several 
pathways, mainly involved in the regulation of reproductive system disease, 
cellular growth and proliferation, cell death and survival, and cellular 
movement. We have chosen the commons genes from both the FT-194 and 
SKOV-3 cells line and predicted affinity of their 5’-flanking regions to PAX8 
binding. We identified potential PAX8 targets based on the presence of PAX8 
binding site(s) in their 5’-flanking sequences and tissue-specificity. Our results 
show that PAX8 is involved in the regulation of a large number of genes in 
both Fallopian tube cells and ovarian cancer cells that will need to be further 
evaluated to fully ascertain PAX8 direct targets.
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6. CONCLUSIONS
Overall, the findings of our study definitely suggest a key role of PAX8 
in the progression of ovarian cancer. Our results clearly indicate that PAX8 
interfering is able to reduce cell growth and survival as well as cellular motility 
and invasion of ovarian cancer cells. Although further studies are needed, some 
PAX8 target genes have been identified.
In conclusion, we believe that the role of PAX8 as a potential 
diagnostic marker and therapeutic target for ovarian cancer represents an 
exciting research area that promises to deliver new insights into the onset and 
growth of such aggressive cancers.
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